Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 41INDUSTRY 16OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Meningeal Carcinomatosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 13Cisplatin 12Carboplatin 12Drug Therapy 10Gemcitabine 8Gefitinib 8Docetaxel 8camrelizumab 5apatinib 5Radiotherapy 5Paclitaxel 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Endostatins 5tislelizumab 4pembrolizumab 4endostar protein 4Simvastatin 4Bevacizumab 4anlotinib 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Etoposide 3toripalimab 2surufatinib 2olaparib 2durvalumab 2atezolizumab 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × aflutinib × Thoracic × Clear all
NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

Phase NA Recruiting
60 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡